Osimertinib plus chemo improves survival across high-risk subgroups in EGFR-mutated aNSCLC
Osimertinib plus chemo improves survival across high-risk subgroups in EGFR-mutated aNSCLC
Avelumab maintenance after reduced chemotherapy cycles improves QoL without sacrificing survival in aUC
Low-dose pembrolizumab plus neoadjuvant chemo option for TNBC in resource-constrained settings
Domvanalimab, zimberelimab and FOLFOX shows durable survival in advanced HER2-negative GC/GEJC/EAC
Abemaciclib combined with endocrine therapy improves OS in high-risk HR+, HER2− early breast cancer
Taletrectinib shows efficacy and tolerability in advanced ROS1+ NSCLC previously treated with entrectinib
Giredestrant plus everolimus new option in ER+, HER2– advanced breast cancer, post-CDK4/6 inhibitors
NSCLC brain metastases: TTFields after SRS delays intracranial progression without affecting QoL
Apalutamide and salvage radiotherapy benefits luminal B subtype prostate cancer
ctDNA testing improves detection of treatable metastases compared to standard care in colorectal cancer
ADT with PORT is a good treatment option for men with unfavourable intermediate risk or favourable high risk PC
Bladder cancer updates from the first half of 2025